Cover Image

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Zhuo Li, Hao‐Ran Dai
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
by: Nina Dominik, et al.
Published: (2024)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
by: Jannis Kountouras, et al.
Published: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
by: Francisco Idalsoaga, et al.
Published: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
by: Yaomin Wang, et al.
Published: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
by: Jian Wang, et al.
Published: (2024)

Review article: Oesophageal disorders in chronic liver disease
by: Francisco Idalsoaga, et al.
Published: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
by: Chen‐Pi Li, et al.
Published: (2024)

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases
by: Ivan Arcari, et al.
Published: (2024)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
by: Nina Dominik, et al.
Published: (2024)

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease
by: Jannis Kountouras, et al.
Published: (2024)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
by: Rui Zhang, et al.
Published: (2024)

Letter: Enhancing patient support through social work—Addressing economic challenges and medication non‐adherence in liver disease management
by: Min Wu, et al.
Published: (2024)

Racial and ethnic disparities in post‐liver transplant outcomes for patients with acute‐on‐chronic liver failure: An analysis of the UNOS database
by: David Uihwan Lee, et al.
Published: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
by: Jian Wang, et al.
Published: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
by: Sung Won Chung, et al.
Published: (2024)

Duke Activity Status Index and Liver Frailty Index predict mortality in ambulatory patients with advanced chronic liver disease: A prospective, observational study
by: Felicity R. Williams, et al.
Published: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
by: Stuart McPherson, et al.
Published: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B
by: Jing Li, et al.
Published: (2024)

Letter: Tenofovir Alafenamide—The “Star of Potential” for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials
by: YaoYao Dai, et al.
Published: (2025)

Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis
by: Shusuke Kumazaki, et al.
Published: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
by: Hyeyeon Hong, et al.
Published: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
by: Carolin V. Schneider, et al.
Published: (2024)

UK guideline on the transition and management of childhood liver diseases in adulthood
by: Deepak Joshi, et al.
Published: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply
by: WenXian OuYang, et al.
Published: (2024)

Letter: Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection
by: Jianrong Li, et al.
Published: (2024)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
by: Zhidong Zhou, et al.
Published: (2025)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
by: Wenjun Meng, et al.
Published: (2024)

Global epidemiology of alcohol‐associated liver disease in adolescents and young adults
by: Pojsakorn Danpanichkul, et al.
Published: (2024)

Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
by: Parminder Kaur, et al.
Published: (2024)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
by: Nobuharu Tamaki, et al.
Published: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
by: Nobuharu Tamaki, et al.
Published: (2024)

Letter: The use of large language models as medical chatbots in digestive diseases
by: Hinpetch Daungsupawong, et al.
Published: (2024)

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
by: Lisa Sandmann, et al.
Published: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
by: Richie Manikat, et al.
Published: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
by: Abdel‐Aziz Shaheen, et al.
Published: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
by: Abhinav Vasudevan, et al.
Published: (2024)

Letter: Allostatic load—A potential key in the development of inflammatory bowel disease
by: Maryam Kharal, et al.
Published: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
by: Yewan Park, et al.
Published: (2024)

Identification of four novel acute‐on‐chronic liver failure clusters with distinct clinical trajectories and mortality using machine learning methods
by: Nipun Verma, et al.
Published: (2024)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis
by: Fang Yan, et al.
Published: (2024)